Mitsubishi UFJ Asset Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $11.5M | Buy |
91,388
+14,466
| +19% | +$1.82M | 0.01% | 559 |
|
|
2025
Q1 | $8.51M | Hold |
76,922
| – | – | 0.01% | 588 |
|
|
2024
Q4 | $10.6M | Buy |
76,922
+9,086
| +13% | +$1.25M | 0.01% | 580 |
|
|
2024
Q3 | $7.82M | Buy |
67,836
+3,438
| +5% | +$396K | 0.01% | 592 |
|
|
2024
Q2 | $8.87M | Buy |
64,398
+9,204
| +17% | +$1.27M | 0.01% | 563 |
|
|
2024
Q1 | $7.61M | Buy |
55,194
+14,015
| +34% | +$1.93M | 0.01% | 574 |
|
|
2023
Q4 | $5.47M | Buy |
41,179
+28
| +0.1% | +$3.72K | 0.01% | 590 |
|
|
2023
Q3 | $4.63M | Buy |
41,151
+85
| +0.2% | +$9.56K | 0.01% | 612 |
|
|
2023
Q2 | $3.87M | Buy |
41,066
+6,113
| +17% | +$576K | 0.01% | 638 |
|
|
2023
Q1 | $3.54M | Buy |
34,953
+4,306
| +14% | +$436K | 0.01% | 633 |
|
|
2022
Q4 | $3.68M | Buy |
30,647
+3,070
| +11% | +$369K | 0.01% | 607 |
|
|
2022
Q3 | $2.93M | Sell |
27,577
-43
| -0.2% | -$4.57K | 0.01% | 637 |
|
|
2022
Q2 | $2.69M | Buy |
27,620
+4,073
| +17% | +$397K | 0.01% | 648 |
|
|
2022
Q1 | $2.21M | Sell |
23,547
-294
| -1% | -$27.6K | 0.01% | 715 |
|
|
2021
Q4 | $2.11M | Buy |
23,841
+2,649
| +13% | +$234K | 0.01% | 745 |
|
|
2021
Q3 | $2.03M | Buy |
21,192
+355
| +2% | +$34.1K | 0.01% | 730 |
|
|
2021
Q2 | $2.03M | Buy |
20,837
+2,409
| +13% | +$234K | 0.01% | 738 |
|
|
2021
Q1 | $1.79M | Buy |
18,428
+1,368
| +8% | +$133K | 0.01% | 713 |
|
|
2020
Q4 | $1.64M | Buy |
17,060
+869
| +5% | +$83.3K | 0.01% | 692 |
|
|
2020
Q3 | $1.56M | Buy |
16,191
+2,094
| +15% | +$201K | 0.01% | 637 |
|
|
2020
Q2 | $1.72M | Buy |
14,097
+1,069
| +8% | +$130K | 0.02% | 576 |
|
|
2020
Q1 | $1.13M | Sell |
13,028
-1,293
| -9% | -$112K | 0.02% | 595 |
|
|
2019
Q4 | $1.57M | Buy |
+14,321
| New | +$1.57M | 0.02% | 597 |
|